Skip to main content
Oncology
Breast Cancer
- A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer (S1706)Accepting Participants
- A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases (S2007)Accepting Participants
- FDG PET to Assess Therapeutic Response in Patients with Bone-dominant Metastatic Breast Cancer, FEATURE (EA1183)Accepting Participants
- Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue (URCC 18007)Accepting Participants
- Screening Mammogram (TMIST) (EA1151)Accepting Participants
- T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial (A011801)Accepting Participants
- Weight Loss - Breast Cancer (A011401) (BWEL)In Progress
- A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer (NGR BR002)Closed
- A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo (NSABP B-59)Closed
- A Randomized, Double-Blind, Phase III Trial of Paclitaxel/ Trastuzumab/ Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer (NRG-BR004)Closed
- Advanced Breast Cancer (A5481082) Closed
- Breast or Gynecologic Cancer, Improving Sexual Desire (NRG-CC004)Closed
- HER2 Negative Primary Breast Cancer, gBRCA1/2 Mutations and High Risk (NSABP B-55)Closed
- HER2- Positive Breast Cancer, Brain Metastasis (RTOG 1119)Closed
- High Risk, Node-Positive, Early Stage (NSABP B-58)Closed
- High-Risk; Hormone Receptor-Positive and HER2/Neu Negative (S1207)Closed
- Post Mastectomy Radiation w/Breast Reconstruction (A221505)Closed
- Post-Mastectomy and Post-Lumpectomy; Positive Axillary Nodes (NSABP B-51)Closed
- Solid Tumors, Blood Sample Collection to Evaluate Biomarkers (2018-01)Closed
- Stage I-II Breast Cancer, MRI and Mammography Before Surgery (A011104)Closed
- Triple Receptor-Negative Breast Cancer (S1418/BR006)Closed
- Triple-Negative Basal-Like Breast Cancer (EA1131)Closed
- Triple-Negative, Node-Positive or High-Risk Node-Negative (NRG-BR003)Closed
- Breast Cancer Survivors, Cognitive Impairment, (REMEMBER) (WF 97116)Complete
- Breast Cancer, Young Women, Pregnancy Outcomes (POSITIVE) (A221405)Complete
- Triple Negative Breast Cancer (RX-5902)Complete
Cancer Care Delivery Research (CCDR)
Cutaneous & Sarcoma Cancer
Gastrointestinal Cancer
- A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE) (EA2182)Accepting Participants
- Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast (ES2018-07)Accepting Participants
- The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal Cancer (A022104)Accepting Participants
- A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers (S1815) Closed
- Advanced Cancer, ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor (QUILT-3.055)Closed
- Advanced Solid Tumors w/ FGF/FGFR Aberrations (TPU-TAS-120-101)Closed
- Colon or Rectal Cancer, Stage I-III, Financial Burden Assessment (EAQ162CD)Closed
- Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair, (A021502)Closed
- Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer (NRG GI004)Closed
- Liver, Non-resectable, (RESIN) RegistryClosed
- Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer (EA2165)Closed
- Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)(NRG GI005)Closed
- Solid Tumors, Blood Sample Collection to Evaluate Biomarkers (2018-01)Closed
- Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer, SOLARIS (A021703)Closed
- Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (EMERALD-2)Complete
- Cholangiocarcinoma, Nonresectable or Metastatic IDH1 Mutation (AG120-C-005)Complete
- Colorectal Cancer, Cognitive Impairment (URCC 16092)Complete
- Pancreatic Adenocarcinoma, Metastatic (ABI-007-PANC009)Complete
- Pancreatic Adenocarcinoma, Metastatic (NLG2104)Complete
- Pancreatic Cancer, Metastatic (RX-3117)Complete
Genitourinary Cancer
- Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (S1806)Accepting Participants
- Dose Dense Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations (A031701)Accepting Participants
- Germ Cell Tumor, Pediatric and Adult Patients (COG AGCT1531)Accepting Participants
- Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study (A031704)Accepting Participants
- Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)(NRG-GU009)Accepting Participants
- Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) (NRG-GU010)Accepting Participants
- Phase II Study of Bladder-SparIng ChemoradiatioN With MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (EA8185 - INSPIRE)Accepting Participants
- Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (A031803)Accepting Participants
- Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial (NRG LU007)Accepting Participants
- A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery (RTOG-3506 STEEL)Closed
- Advanced Cancer, ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor (QUILT-3.055)Closed
- Advanced Solid Tumors w/ FGF/FGFR Aberrations (TPU-TAS-120-101)Closed
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (EA8143)Closed
- Prostate, Chemo Naive, mCRPC (PANTHER)Closed
- Prostate, Post-Prostatectomy (NRG-GU002)Closed
- Prostate, Unfavorable Intermediate or Favorable High Risk (RTOG 0924)Closed
- Prostate; High-Risk Biochemically Relapsed (AFT-19)Closed
- Solid Tumors, Blood Sample Collection to Evaluate Biomarkers (2018-01)Closed
- Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors (A031102)Closed
- Urothelial, Muscle Invasive and Locally Advanced (A031501)Closed
Hematologic Cancer
- Myelodysplastic Syndromes & Acute Myeloid Leukemia, (Connect® MDS/AML) ObservationalAccepting Participants
- Study of Lenalidomide/ Ixazomib/ Dexamethasone/ Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM (AFT-41)Accepting Participants
- A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects With Chronic Lymphocytic Leukemia (AZ ASSURE)Closed
- A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (MMY3021)Closed
- A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (Celegene CC-92480-MM-001)Closed
- A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not PlannedClosed
- Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies (2018-02)Closed
- Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma (S1826)Closed
- Leukemia, Acute Lymphocytic (ALL), Adolescent & Young Adult (ACCL16N1CD)Closed
- Leukemia, Acute Promyelocytic (EA9131) ObservationalClosed
- Leukemia, Chronic Lymphocytic (CLL), Untreated Older Patients (A041702)Closed
- Leukemia, Chronic Lymphocytic (CLL), Untreated Younger Patients (EA9161)Closed
- Leukemia, Chronic Lymphocytic (PCYC-1134M), RegistryClosed
- Lymphoma, Hodgkin (CA209655) ObservationalClosed
- Multiple Myeloma, Refractory to Lenalidomide (A061202)Closed
- Multiple Myeloma, Untreated, Stem Cell Transplant Not Planned (54767414MMY3019)Closed
- Multiple Myeloma: 1st Line Therapy (E1A11)Closed
- Myelodysplastic Syndromes (MDS) (NHLBI-MDS) ObservationalClosed
- Myelofibrosis or Essential Thrombocythemia (INCB-MA-MF-401) RegistryClosed
- Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (S1608)Closed
- Randomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)Closed
- Leukemia, Chronic Myeloid (S1712)Complete
- Lymphoma, Diffuse Large B-Cell, Relapsed or Refractory (1562-201)Complete
- Lymphoma, Diffuse Large B-Cell, Treatment Naïve (DB102-02)Complete
- Lymphoma, Mantle Cell, Previously Treated (AFT-32)Complete
- Plasmacytoma of the Bone (A061402)Complete
Precision Medicine & Rare Tumors
- Non-small Cell Lung Cancer ALCHEMIST (A151216)Accepting Participants
- Solid and Liquid Tumors: Newly Diagnosed With No Treatment Started (GRAIL-001) ObservationIn Progress
- Advanced Cancer, ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor (QUILT-3.055)Closed
- Advanced Solid Tumors w/ FGF/FGFR Aberrations (TPU-TAS-120-101)Closed
- HER2 Negative Primary Breast Cancer, gBRCA1/2 Mutations and High Risk (NSABP B-55)Closed
- Lymphoma, Hodgkin (CA209655) ObservationalClosed
- Melanoma, Stage III-IV BRAF Mutant (S1320)Closed
- Merkel Cell Carcinoma, Advanced (A091605)Closed
- Merkel Cell Carcinoma, Resected (EA6174)Closed
- Non-small Cell Lung Cancer NSCLC, EGFR Mutant (A081105)Closed
- Solid Tumors (eFT508-0010)Closed
- Solid Tumors or Lymphomas; MATCH (EAY131)Closed
- Solid Tumors, Rare Tumor Types, DART (S1609)Closed
- Leukemia, Chronic Myeloid (S1712)Complete
- Lymphoma, Diffuse Large B-Cell, Treatment Naïve (DB102-02)Complete
- Lymphoma, Mantle Cell, Previously Treated (AFT-32)Complete
Symptom Management & Cancer Control
- A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (NRG-CC008)Accepting Participants
- All Disease Sites; Health Disparities (DCP-001)Accepting Participants
- Blinded Reference Set for Multicancer Early Detection Blood Tests (A212102)Accepting Participants
- Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/antiPD-L1 Immunotherapy in a Community Oncology Setting (URCC-21038)Accepting Participants
- Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps, FORTE (NRG-CC005)Accepting Participants
- Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials (EAQ202)Accepting Participants
- Mepitel Film for the Reduction of Radiation Dermatitis in Breast Cancer Patients Undergoing Post-Mastectomy Radiation Therapy: A Randomized Phase III Clinical Trial (A221803)Accepting Participants
- Myopenia and Mechanism of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study (WF-1806)Accepting Participants
- NCI Community Oncology Research Program (NCORP) Tissue Procurement Protocol: An NCI Cancer MoonshotSM StudyAccepting Participants
- Optimizing Endocrine Therapy Adherence Through Motivational Interviewing and Text Interventions (GETSET) (A191901)Accepting Participants
- Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue (URCC 18007)Accepting Participants
- Screening Mammogram (TMIST) (EA1151)Accepting Participants
- Weight Loss - Breast Cancer (A011401) (BWEL)In Progress
- Assessment Of Cognitive Function In Breast Cancer And Lymphoma Patients Receiving Chemotherapy At Pre-Treatment, Post-Treatment, At Six Month Follow-Up, And Long-Term Follow-Ups (URCC 10055)Closed
- Breast or Gynecologic Cancer, Improving Sexual Desire (NRG-CC004)Closed
- Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer (WF-1802 PCW)Closed
- EROS: Engendering Reproductive Health within Oncologic Survivorship (E1Q11)Closed
- Lung Cancer, Survivors (RELAX) (WF01213)Closed
- NCI COVID-19 in Cancer Patients, NCCAPS Study (NCI COVID, N-CCaPS)Closed
- Non-small Cell Lung Cancer NSCLC; Stages I-II; African-American, (WF01414) ObservationClosed
- Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases From Small Cell Lung Cancer (NRG-CC009)Closed
- Stage I-II Breast Cancer, MRI and Mammography Before Surgery (A011104)Closed
- Survivors, Work Ability in Young Adult Survivors (WF 10217)Closed
- Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer (S1714)Closed
- Wireless Transcutaneous Electrical Nerve Stimulation (TENS) for Chemotherapy-Induced Peripheral Neuropathy: A Phase II Clinical Trial (URCC 19085 TENS)Closed
- Breast Cancer Survivors, Cognitive Impairment, (REMEMBER) (WF 97116)Complete
- Breast Cancer, Young Women, Pregnancy Outcomes (POSITIVE) (A221405)Complete
- Colorectal Cancer, Cognitive Impairment (URCC 16092)Complete
- Ovarian, Fallopian Tube, and Primary Peritoneal, Diet & Physical Activity (GOG-0225)Complete
Thoracic Cancer
- A Randomized Phase III Trial of Induction/ Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC (S1914)Accepting Participants
- AMG 510 in Combination with Carboplatin and Pemetrexed or with Docetaxel in Subjects with NSCLC with KRAS p.G12C Mutation (Amgen Subprotocol F)Accepting Participants
- MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK) (S1827)Accepting Participants
- Non-small Cell Lung Cancer ALCHEMIST (A151216)Accepting Participants
- Non-small Cell Lung Cancer, Early Stage, Resected, Harboring ALK (E4512)Accepting Participants
- Phase 1/2 Study of Stereotactic Body Radiation Therapy (SBRT) With or Without GC4711 for Early Stage, Centrally Located or Large Non-Small Cell Lung Cancer (NSCLC)(GRECO-1)Accepting Participants
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung CancerAccepting Participants
- Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer (EA5163/ S1709)Accepting Participants
- A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (Mermaid-1)Closed
- Adenoma and Second Primary Prevention Trial (S0820)Closed
- Advanced Cancer, ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor (QUILT-3.055)Closed
- AMG 510 (pINN) Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (Amgen 20190135 Subprotocol E)Closed
- Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (A081801)Closed
- Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab (NRG-LU005)Closed
- Lung Cancer, Survivors (RELAX) (WF01213)Closed
- LUNGMAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer, (Screening Study)Closed
- Non-small Cell Lung Cancer NSCLC, EGFR Mutant (A081105)Closed
- Non-small Cell Lung Cancer NSCLC; Stages I-II; African-American, (WF01414) ObservationClosed
- Non-small Cell Lung Cancer, Previously Treated (SWOG Lung-Map)Closed
- Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide (CALGB-30610)Closed
- Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2)Closed
- Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases From Small Cell Lung Cancer (NRG-CC009)Closed
- Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) (S1800A)Closed
- Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (S1900A)Closed
- Small Cell Lung Cancer, Relapsed or Refractory, Second-Line (DIV-SCLC-301)Closed
- Solid Tumors, Blood Sample Collection to Evaluate Biomarkers (2018-01)Closed
- Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung CancerComplete
- Non-small Cell Lung Cancer (NSCLC), Metastatic (NRG LU-002)Complete
Other
Wound Healing - Infectious Disease
